Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm trial of poziotinib in recurrent or metastatic esophageal cancer
KCT0003833Phase 2Withdrawn
- Sponsor
- Hanmi Pharmaceutical
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of poziotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Hanmi Pharmaceutical. Planned start Sep 2026; status: withdrawn.
02
Drugs
poziotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on KCT0003833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003833.